Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04935736
Other study ID # CORT-SP
Secondary ID 2021-A00525-36
Status Completed
Phase N/A
First received
Last updated
Start date June 30, 2021
Est. completion date January 15, 2022

Study information

Verified date February 2022
Source ACTEON Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study design is a multicentric randomized controlled clinical trial. 238 subjects (teeth) requiring a primary or a secondary root canal treatment will be enrolled in 2 groups (119 in each group). The aim is to assess the effectiveness and utility of the ancillary drug substance, prednisolone acetate (1%) contained in CORTISOMOL SP (Zinc Oxide/Eugenol-type sealer) to help to decrease the possible postoperative painful reactions after root canal treatment. SEALITE REGULAR, which has a similar formulation except it is prednisolone acetate-free, is used as the comparator sealer. Procedures of root canal treatment will be conventional and standardized for all investigational centers. The canals will be cleaned, shaped and then obturated using a Zinc oxide/Eugenol-type sealer (CORTISOMOL SP or SEALITE REGULAR) and gutta-percha. Patients assess their pain for 7 days after permanent root canal obturation.


Recruitment information / eligibility

Status Completed
Enrollment 243
Est. completion date January 15, 2022
Est. primary completion date January 15, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or female, age > 18 years old - Patient requiring a primary or a secondary root canal treatment on a single or multi-rooted tooth. - Informed consent signed - Patient with social protection. Exclusion Criteria: - Endodontic treatment on tooth with suspected root perforation, or immature tooth, - Known allergy to corticosteroids, local anesthetics, or any component of the medical devices, - Patient taking anti-pain or anti-inflammatory treatment regularly for another pathology, - Presence of any significant medical finding or significant history such as uncontrolled systemic diseases that may impact the safety, the interpretation of the results and/or the participation of the subject in the study according to the opinion of the investigator, - Participation in another intervnetional clinical trial or subject still within the exclusion period of a previous clinical trial, - Vulnerable subjects referred to in articles L.1121-5 to 8 and L.1122-1-2 of the Public Health Code and article 66 of Regulation (EU) 2017/745 on medical devices are excluded from the investigation (such as known pregnancy or lactation, patients with legal protection).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
root canal sealer : CORTISOMOL SP
The participant will be treated with CORTISOMOL SP sealer in combination with gutta percha.
root canal sealer : SEALITE REGULAR
The participant will be treated with SEALITE REGULAR sealer in combination with gutta percha.

Locations

Country Name City State
France Cabinet dentaire Lamballe
France Cabinet dentaire Liffré
France Cabinet dentaire Plédran
France Cabinet dentaire Pluguffan
France Cabinet dentaire Rennes
France CHU Rennes - Centre de Soins Dentaires Rennes
France Cabinet dentaire Saint-Brieuc
France Cabinet dentaire Saint-Coulomb

Sponsors (2)

Lead Sponsor Collaborator
ACTEON Group Slb Pharma

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Post-operative pain assessed by a VAS The pain is assessed by patients in a diary using a Visual Analogue Scale (range from 0 (= no pain) to 100 (= the worst pain)) at different times after endodontic treatment from the end of the root canal obturation to Day 7. The maximum pain felt will be compared between the 2 groups. From the end of the root canal treatment (Day 0) to Day 7
Secondary Use of oral pain treatment Patients reported the consumption of analgesic treatment in a diary. The proportion of patients who took oral pain medication will be compared between the 2 groups. From the end of the root canal treatment (Day 0) to Day 7
Secondary Number of adverse events Adverse events recorded from the endodontic treatment to the end of follow-up visit will be used to assess the safety of root canal sealers and endodontic procedures. From the end of the root canal treatment (Day 0) to the end of follow-up visit (Day 14)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04757753 - Root Canal Obturation With a Ready-to-use Root Canal Sealer (PA1704) Versus BioRootâ„¢ RCS: a Randomized Controlled Trial N/A
Completed NCT04885686 - Endodontic Post-operative Pain Evaluation of Patients After Using Endomethasone N or Endomethasone SP (EndoPOP) N/A
Completed NCT01728532 - Open, Multicentric Trial Evaluating the Efficacy and the Clinical Tolerance of PA0903 as Root Canal Sealer N/A
Completed NCT04753138 - Outcome of SBO With Calcium Silicate Sealer vs WVC With Resin Based Sealer N/A
Recruiting NCT05247138 - Measurement of the Clinical and Radiological Performance Impact of the Root Canal Treatment With BioRootTM RCS.
Completed NCT03732170 - Root Canal Treatment With TotalFill® Bioceramic Sealer and AH Plus® Sealer N/A
Completed NCT03874949 - Pain After Root Canal Obturation With Sealer Containing or Not 1% Enoxolone N/A